Nikos Kühl

Nikos Kühl

Auto-generated profile, based on publicly available information

Nikos Kühl

Medicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology IPMB, Heidelberg University, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NKNikos KühL
Nikos KühL
DGDominik Graf
Dominik Graf
JBJosephine Bock
Josephine Bock
MBMira Behnam
Mira Behnam
MLMila-Mareen Leuthold
Mila-Mareen Leuthold
CKChristian D. Klein
Christian D. Klein

14 April 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NKNikos Kühl
Nikos Kühl
MLMila M. Leuthold
Mila M. Leuthold
MBMira Behnam
Mira Behnam
CKChristian D. Klein
Christian D. Klein

23 March 2022 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
TDTonko Dražić
Tonko Dražić
NKNikos Kühl
Nikos Kühl
MLMila M. Leuthold
Mila M. Leuthold
MBMira A. M. Behnam
Mira A. M. Behnam
CKChristian D. Klein
Christian D. Klein
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has a huge impact on the world. Although several vaccines have recently reached the market, the development of specific antiviral drugs against SARS-CoV-2 is an important additional strategy in fighting the pandemic. One of the most promising pharmacological targets is the viral main protease (Mpro). Here, we present an optimized biochemical assay procedure for SARS-CoV-2 Mpro. We have comprehensively investigated the influence of different buffer components and conditions on the assay performance and characterized Förster resonance energy transfer (FRET) substrates with a preference for 2-Abz/Tyr(3-NO2) FRET pairs. The substrates 2-AbzSAVLQSGTyr(3-NO2)R-OH, a truncated version of the established DABCYL/EDANS FRET substrate, and 2-AbzVVTLQSGTyr(3-NO2)R-OH are promising candidates for screening and inhibitor characterization. In the latter substrate, the incorporation of Val at position P5 improved the catalytic efficiency. Based on the obtained results, we present here a reproducible, reliable assay protocol using highly affordable buffer components.

5 December 2024 in Antiviral Research
Verified
Journal Article
Open access
JLJohannes Lang
Johannes Lang
SDSudip Kumar Dutta
Sudip Kumar Dutta
MLMila M. Leuthold
Mila M. Leuthold
LRLisa Reichert
Lisa Reichert
NKNikos Kühl
Nikos Kühl
CKChristian D. Klein
Christian D. Klein
The viral NS2B-NS3 protease is a promising drug target to combat dengue virus (DENV) and other emerging flaviviruses. The discovery of novel DENV protease inhibitors with antiviral efficacy is hampered by the low predictive power of biochemical assays. We herein present a comparative evaluation of biochemical DENV protease assay conditions and their benchmarking against antiviral efficacy and a protease-specific reporter gene assay. Variations were performed with respect to pH, type of detergent, buffer, and substrate. The revised assay conditions were applied in a medicinal chemistry effort aimed at phenylglycine protease inhibitors. This validation study demonstrated a considerably improved predictive power for antiviral efficacy in comparison to previous approaches. An extensive evaluation of phenylglycine-based DENV protease inhibitors with highly diverse N-terminal caps indicates further development potential in this structural region. Furthermore, the phenylglycine moiety may be less essential than previously assumed, providing a development option towards reduced lipophilicity and thereby an improved pharmacokinetic and toxicity profile.

1 October 2021 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
TDTonko Drazic
Tonko Drazic
NKNikos Kühl
Nikos Kühl
NGNicole Gottscheber
Nicole Gottscheber
CHChristina N. Hacker
Christina N. Hacker
CKChristian D. Klein
Christian D. Klein

19 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
TDTonko Drazic
Tonko Drazic
NKNikos Kühl
Nikos Kühl
MLMila M. Leuthold
Mila M. Leuthold
MBMira Behnam
Mira Behnam
CKChristian D. Klein
Christian D. Klein
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has a huge impact on the world. Although several vaccines have recently reached the market, the development of specific antiviral drugs against SARS-CoV-2 is an important additional strategy in fighting the pandemic. One of the most promising pharmacological targets is the viral main protease (M pro ). Here, we present an optimized biochemical assay procedure for SARS-CoV-2 M pro . We have comprehensively investigated the influence of different buffer components and conditions on the assay performance, and characterized six FRET substrates with a 2-Abz/Tyr(3-NO 2 ) FRET pair. The substrates 2-AbzSAVLQSGTyr(3-NO 2 )R-OH, a truncated version of the established DABCYL/EDANS FRET substrate, and a new substrate 2-AbzVVTLQSGTyr(3-NO 2 )R-OH are promising candidates for screening and inhibitor characterization. In the latter substrate, the incorporation of Val at the position P5 improved the catalytic efficacy. Based on the obtained results, we present here a reproducible, reliable assay protocol using highly affordable buffer components.